Non-peptide

Orforglipron

Also known as

LY3502970 · Foundayo (branded oral orforglipron — weight indication discussion) · Oral non-peptide GLP-1 agonist · Oral small-molecule GLP-1 RA · Lilly oral GLP-1 (discussion shorthand) · Orforglipron pill (forum shorthand) · Orf / orfor (forum shorthand)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	A daily oral non-peptide GLP-1 compound, sold as Foundayo, discussed for weight management without injections.
Why a pill appeals	Needle anxiety and flexible timing attract some users; others find a daily tablet harder to remember than a weekly injection.

Notes

Orforglipron is a daily oral GLP-1 compound, sold as Foundayo, that people discuss for weight management without injections. Users describe quieter food thoughts and earlier meal stopping, but some notice little change or find the stomach effects too disruptive.

A small molecule, not a peptide. Orforglipron is an oral non-peptide compound that activates the GLP-1 receptor. Its effects involve appetite, glucose and stomach emptying. Foundayo is the branded tablet; historical studies also used investigational capsules. Pratt et al. Phase 1a study — primary abstract (Official context · Accessed 2026-09-30) · ADA 2026: ATTAIN-1 post-hoc poster — accessible body (Official context · Accessed 2026-09-30)

Convenience is part of the appeal. Needle anxiety, cost and avoiding a fasting routine recur in discussions. A shift worker welcomes flexible timing; other users prefer a weekly injection because remembering a tablet every day feels harder. Day 1 experience on Foundayo (Community discussion · Accessed 2026-09-30) · Saxenda, Ozempic, Wegovy & Mounjaro advice and support #42 — page 53 (Community opinion · Accessed 2026-09-30) · The one problem with orforglipron nobody warned me about (Personal report · Accessed 2026-09-30)

Source context — Pratt et al. Phase 1a study — primary abstract: Primary abstract only, not full paper or raw PK data. Healthy-participant historical formulations and cohorts; not individual community measurement.

Source context — ADA 2026: ATTAIN-1 post-hoc poster — accessible body: Sponsor presentation; specified formulation mapping only, not arbitrary products or cross-drug conversions. Not individual outcome or head-to-head comparison.

Source context — Day 1 experience on Foundayo: Uncontrolled reports; costs and coverage personal and date-specific. No verified body-composition measurements or superiority conclusion.

Source context — Saxenda, Ozempic, Wegovy & Mounjaro advice and support #42 — page 53: Opinion about future convenience, not use outcome; UK status/prices not adopted. Simplified absorption explanation not used to establish pharmacology.

Source context — The one problem with orforglipron nobody warned me about: Same author as day1/capsules with vendor promotion elsewhere. Identity/amount unverified; perceived wear-off cannot measure clearance. Predicted weekend restart harm is not an observed outcome.

What people notice

Quieter food thoughts	Some describe less repeated thinking about eating and stopping meals earlier while still feeling hunger and enjoying food.
Weight outcomes differ	One person reports seven pounds lost in 30 days at 0.8 mg; another reports no loss after a month at 0.8 mg plus a week at 2.5 mg.
Switching can disappoint	A former Zepbound user describes hunger, food noise, regain and stomach trouble after switching; others tolerate the pill or maintain weight.

Notes

Less mental pull toward food. Food noise means repeated thoughts about eating or snacking. One first-day user still felt hungry and enjoyed sushi, yet lost interest halfway through the meal. Another described easier meal stopping without nausea in an unverified product log. Day 1 experience on Foundayo (Community discussion · Accessed 2026-09-30) · Testing the new orforglipron pill day 1 log (Personal report · Accessed 2026-09-30)

Weight change is a separate question. In one thread, a respondent reports seven pounds lost over 30 days at 0.8 mg; another reports no weight loss or side effects after a month at 0.8 mg and a further week at 2.5 mg. Early appetite change does not settle the longer outcome. Foundayo first week (Community discussion · Accessed 2026-09-30)

A convenient switch can still disappoint. A former Zepbound user liked the pill but reported hunger, food noise, brain fog, regain and stomach trouble despite reducing the amount. Other respondents tolerate it or maintain weight; convenience does not predict the result. Goodbye Foundayo, hello again Zepbound (Community discussion · Accessed 2026-09-30)

Source context — Day 1 experience on Foundayo: Uncontrolled reports; costs and coverage personal and date-specific. No verified body-composition measurements or superiority conclusion.

Source context — Testing the new orforglipron pill day 1 log: Unverified product and dose. Same author links a vendor in the capsule thread; possible promotion, not three independent users. First-day experience only; anticipated day-three effect is hearsay.

Source context — Foundayo first week: Self-reported amounts/outcomes; lifestyle changes and no verified adherence. Reply predicting benefit only at maximum is unsupported. Relative post dates not converted.

Source context — Goodbye Foundayo, hello again Zepbound: Prior injectable treatment and changing drugs confound comparison. Post expresses intent to restart Zepbound, not a completed successful restart. No universal potency ranking or mg equivalence.

Doses people talk about

0.8 and 2.5 mg tablets daily	Appear in early Foundayo logs, sometimes a month at 0.8 mg before 2.5 mg. Some stay longer at the earlier strength; these are individual histories.
5.5 and 9 mg tablets	Appear later in use. One switcher reduced 9 mg to 5.5 mg for poor tolerance; another maintained weight at 9 mg without further loss.
Unverified capsule amounts	A daily-capsule author does not confirm milligrams. A reply asking about 6 mg is not a confirmed dose.
Specific trial-form mapping	Lilly maps a 17.2 mg tablet to its 36 mg investigational capsule. That applies to specified formulations, not arbitrary powders or other GLP-1 drugs.

Notes

Foundayo tablets: 0.8 mg and 2.5 mg once daily appear in early logs. Respondents describe a month at 0.8 mg before 2.5 mg; others stay at the earlier strength longer. These individual reports are not a step-up plan. Foundayo first week (Community discussion · Accessed 2026-09-30)

5.5 mg and 9 mg tablets appear in later-use discussions. A switcher reduced 9 mg to 5.5 mg for poor tolerance; another maintained weight at 9 mg without further loss. Both strengths also appear in nausea discussions. Goodbye Foundayo, hello again Zepbound (Community discussion · Accessed 2026-09-30) · Just started 0.8mg this week. Do side effects get better? (Community discussion · Accessed 2026-09-30)

Capsules and headline trial milligrams are separate. One unverified author reports a capsule daily without confirming mg. A reply's 6 mg question is not their confirmed dose. Earlier community discussion warns against comparing unlike formulations or GLP-1 drugs by raw milligrams. Tried the orforglipron capsules (Personal report · Accessed 2026-09-30)

Specific capsule/tablet mapping, not a general conversion. Lilly's poster identifies a 17.2 mg tablet as equivalent to the 36 mg investigational capsule. That mapping applies to specified formulations, not unknown powders or other GLP-1 drugs; the headline numbers are not interchangeable personal doses. ADA 2026: ATTAIN-1 post-hoc poster — accessible body (Official context · Accessed 2026-09-30)

Source context — Just started 0.8mg this week. Do side effects get better?: Timing and food confounded. Hair-loss timing differs even within one author's replies; preserve concern without endorsing instant causation. Medication/support suggestions not adopted as advice.

Source context — Tried the orforglipron capsules: Commercially promotional context; affiliate/sponsorship unknown. No independently verified bottle, contents or mg. A reply asks about 6 mg but OP does not confirm it. Not a Foundayo tablet study.

Half-life, onset & duration

Felt onset	Some notice earlier fullness within hours; another first notices less hunger on day six. A separate month-long account reports no weight or side-effect change.
Felt duration	Some daily users describe evening or all-day control, including one missed day at 2.5 mg. Other wear-off accounts conflict; no fixed single-tablet window is established.
Half-life	Labeling gives 29–49 hours. A healthy-participant study gives 24.6–35.3 hours after single doses and 48.1–67.5 after repeated daily doses. These are formal measurements, not an appetite clock.
Blood peak	A timing thread repeats Lilly's 4–8-hour peak. It describes blood concentration, not when evening hunger must return.

Notes

Hours for some; several days for others. The sushi account notices a change by lunch after breakfast dosing. An earlier 8 am log describes fullness within hours, without headache or nausea; its amount is withheld. In another thread the OP first notices less hunger on day six. Day 1 experience on Foundayo (Community discussion · Accessed 2026-09-30) · Testing the new orforglipron pill day 1 log (Personal report · Accessed 2026-09-30) · Foundayo first week (Community discussion · Accessed 2026-09-30)

No dependable early deadline. The capsule author describes suppression building over days to a week and meals becoming an afterthought by day four in another post. This is the same vendor-linked author as the first-day log; the month-long null report is a different user. Tried the orforglipron capsules (Personal report · Accessed 2026-09-30) · The one problem with orforglipron nobody warned me about (Personal report · Accessed 2026-09-30) · Foundayo first week (Community discussion · Accessed 2026-09-30)

Some daily users describe control through evening. Morning users report evening or all-day control. One 2.5 mg user still felt reduced appetite during an accidentally missed day. Neither establishes a fixed single-tablet benefit window. Peak plasma time? (Community discussion · Accessed 2026-09-30) · alternating days on Foundayo? (Community discussion · Accessed 2026-09-30)

Wear-off reports conflict. The unverified capsule author reports hunger after dosing four hours late. A reply questions that interpretation; the author concedes formulation or daily variation might matter. Hunger does not measure clearance. The one problem with orforglipron nobody warned me about (Personal report · Accessed 2026-09-30)

After stopping, persistence is uncertain. A capsule-thread respondent describes returning food noise when the bottle ran out, without a precise interval. Earlier reports also discuss rebound; neither supplies a dependable washout-to-hunger timetable. Tried the orforglipron capsules (Personal report · Accessed 2026-09-30)

Roughly 25–50 hours, or 29–49 hours, is repeated online. A timing thread repeats study-style half-life figures and Lilly's 4–8-hour peak when considering evening cravings. Another thread explicitly attributes 29–49 hours to Lilly. These are circulated formal measurements, not measurements by forum users. Peak plasma time? (Community discussion · Accessed 2026-09-30) · alternating days on Foundayo? (Community discussion · Accessed 2026-09-30)

Human half-life measurements have different contexts. Current labeling reports 29–49 hours. Pratt's healthy-participant study reports 24.6–35.3 hours after single dosing and 48.1–67.5 hours after repeated daily dosing. These formal measurements come from different study contexts, not a personal appetite clock. Pratt et al. Phase 1a study — primary abstract (Official context · Accessed 2026-09-30) · Foundayo prescribing information — revised July 2026 (Official context · Accessed 2026-09-30)

Source context — Day 1 experience on Foundayo: Uncontrolled reports; costs and coverage personal and date-specific. No verified body-composition measurements or superiority conclusion.

Source context — Peak plasma time?: Numeric half-life is secondhand formal-study repetition, not a community measurement. Confident claim of flat levels and minimal timing impact not proven by these reports; possible generated prose not authenticated.

Source context — alternating days on Foundayo?: OP writes .08 mg, not silently corrected to 0.8 mg. Tablet mg-to-blood-level calculation rejected. No validated schedule or reported long-term outcome of alternate-day use.

Source context — Foundayo prescribing information — revised July 2026: Official prescribing context, not individualized directions or community practice. PK largely corresponding investigational-formulation data. Animal warnings do not prove human tumor causation.

Cycles people discuss

Ongoing use	Discussion follows monthly progress and injection-to-pill switches rather than a standard short on/off course.
Alternate-day experiment	One 2.5 mg user tries alternate days for excessive appetite suppression. No validated break length or lasting weight-control outcome follows.

Notes

Discussion centers on ongoing use. Community discussion favors tolerable ongoing appetite control over a short bodybuilding cut. Logs track monthly follow-ups and injection-to-pill switches; no standard on/off course emerges. Foundayo first week (Community discussion · Accessed 2026-09-30) · Goodbye Foundayo, hello again Zepbound (Community discussion · Accessed 2026-09-30)

Alternate-day experiments are reported, not validated. One 2.5 mg respondent tries alternate days for excessive appetite suppression; others only ask about it. No established break length or lasting weight-control outcome is provided. alternating days on Foundayo? (Community discussion · Accessed 2026-09-30)

Stacks

Food, training and GI supports	Community additions include protein, resistance training, electrolytes, fiber, ginger and smaller meals. Some find dense protein foods uncomfortable.
Other GLP-1 drugs	Switching from injections is a sequence, not a combination. Same-week tirzepatide talk raises overlapping GI-burden concerns; the label discourages another GLP-1 receptor agonist alongside it.
Other medicines and peptides	Metformin and other diabetes medicines appear in formal programs; occasional BPC-157, growth-hormone secretagogue or AOD/fragment talk does not establish a useful combination.

Notes

Community adjuncts: High protein, resistance training, electrolytes, fiber timing, and GI supports (ginger, smaller low-fat meals) for lean-mass and tolerability. [community]

Eating enough can become the harder task. Users discuss smaller portions, protein, fiber, hydration, electrolytes, ginger and resistance training. One workout-focused respondent found dense protein foods uncomfortable and felt stressed by rigid protein targets. Earlier reports also associate greasy meals or alcohol-heavy dinners with reflux; these are experiences, not universal restrictions. Day 1 experience on Foundayo (Community discussion · Accessed 2026-09-30) · Just started 0.8mg this week. Do side effects get better? (Community discussion · Accessed 2026-09-30)

Injectable → oral sequence: ATTAIN-MAINTAIN models switch from Wegovy or Zepbound to oral orf for maintenance — sequenced, not stacked. [trial]

Orf + tirz in the same week: Community caution focuses on overlapping incretin pathways and stacked GI burden; these concerns are not a validated co-use protocol. [community]

Thyroid warning and overlapping GLP-1 drugs. Personal/family medullary thyroid cancer or MEN2 contraindicates use. Negative rodent findings do not establish human safety. The label discourages another GLP-1 receptor agonist alongside it. Foundayo prescribing information — revised July 2026 (Official context · Accessed 2026-09-30)

Metformin / other T2D meds: Clinician territory in diabetes programs; hypoglycemia risk rises mainly with insulin/secretagogues (class). [trial]

Other research peptides: Occasional BPC-157 (gut), GHS, AOD/frag talk alongside any GLP-1 — outcomes heavily confounded. [community]

Source context — Day 1 experience on Foundayo: Uncontrolled reports; costs and coverage personal and date-specific. No verified body-composition measurements or superiority conclusion.

Watch for

Stomach symptoms and fatigue	Nausea, reflux, vomiting, diarrhea, constipation, fatigue and light-headedness can be disruptive or prompt stopping. Some symptoms worsen after increasing the amount.
Severe pain or fluid loss	Warnings include pancreatitis, gallbladder disease, dehydration-related kidney injury and anesthesia aspiration. Persistent severe abdominal pain or inability to retain fluids needs medical attention.
Thyroid and medication review	Personal/family medullary thyroid cancer or MEN2 contraindicates use. Pregnancy, diabetes medicines, contraceptives and interactions need clinician review.
Product identity	Powder/capsule claims and vendor-linked testimonials do not verify contents, amount or equivalence to branded tablets.

Notes

Stomach effects can remain disruptive. Reports include nausea, reflux, vomiting, diarrhea or constipation. Some improve; others worsen after an increase or never fully settle. Respondents also describe fatigue, hair-loss concerns or light-headedness severe enough to quit. These experiences do not establish each symptom's cause. Just started 0.8mg this week. Do side effects get better? (Community discussion · Accessed 2026-09-30) · Foundayo first week (Community discussion · Accessed 2026-09-30)

Serious symptoms and other medicines matter. Warnings include pancreatitis, dehydration-related kidney injury, gallbladder disease, severe stomach problems and anesthesia aspiration. Persistent severe abdominal pain or inability to retain fluids warrants medical attention. Pregnancy, diabetes medicines, contraceptives and interactions need clinician review. Foundayo prescribing information — revised July 2026 (Official context · Accessed 2026-09-30)

A powder or capsule claim does not verify its contents. Community discussion questions identity and dose accuracy outside branded tablets. Vendor-linked testimonials and claimed testing cannot establish that an unknown product matches Foundayo. Tried the orforglipron capsules (Personal report · Accessed 2026-09-30)

Full notes

What the pill does

A small molecule, not a peptide. Orforglipron is an oral non-peptide compound that activates the GLP-1 receptor. Its effects involve appetite, glucose and stomach emptying. Foundayo is the branded tablet; historical studies also used investigational capsules. Official context Official context
Convenience is part of the appeal. Needle anxiety, cost and avoiding a fasting routine recur in discussions. A shift worker welcomes flexible timing; other users prefer a weekly injection because remembering a tablet every day feels harder. Community · Reddit Community · Tattle Life Personal report

What people hope to notice

Less mental pull toward food. Food noise means repeated thoughts about eating or snacking. One first-day user still felt hungry and enjoyed sushi, yet lost interest halfway through the meal. Another described easier meal stopping without nausea in an unverified product log. Community · Reddit Personal report
Weight change is a separate question. In one thread, a respondent reports seven pounds lost over 30 days at 0.8 mg; another reports no weight loss or side effects after a month at 0.8 mg and a further week at 2.5 mg. Early appetite change does not settle the longer outcome. Community · Reddit

Doses people discuss

These describe oral use and reported amounts, not a step-up plan. The capsule/tablet distinction is explained below.

Foundayo tablets: 0.8 mg and 2.5 mg once daily appear in early logs. Respondents describe a month at 0.8 mg before 2.5 mg; others stay at the earlier strength longer. These individual reports are not a step-up plan. Community · Reddit
5.5 mg and 9 mg tablets appear in later-use discussions. A switcher reduced 9 mg to 5.5 mg for poor tolerance; another maintained weight at 9 mg without further loss. Both strengths also appear in nausea discussions. Community · Reddit Community · Reddit
Capsules and headline trial milligrams are separate. One unverified author reports a capsule daily without confirming mg. A reply's 6 mg question is not their confirmed dose. Earlier community discussion warns against comparing unlike formulations or GLP-1 drugs by raw milligrams. Personal report Community

Half-life: the origin matters

Roughly 25–50 hours, or 29–49 hours, is repeated online. A timing thread repeats study-style half-life figures and Lilly's 4–8-hour peak when considering evening cravings. Another thread explicitly attributes 29–49 hours to Lilly. These are circulated formal measurements, not measurements by forum users. Community · Reddit Community · Reddit
A tracker preset is a modeling choice. Peptrend uses 38.4 hours, replacing an older 55-hour preset. Its guide identifies the newer constant as derived from a label range. Neither number measures a person's clearance or predicts when hunger returns. Community guide

Onset: when a change is noticed

Hours for some; several days for others. The sushi account notices a change by lunch after breakfast dosing. An earlier 8 am log describes fullness within hours, without headache or nausea; its amount is withheld. In another thread the OP first notices less hunger on day six. Community · Reddit Personal report Community · Reddit
No dependable early deadline. The capsule author describes suppression building over days to a week and meals becoming an afterthought by day four in another post. This is the same vendor-linked author as the first-day log; the month-long null report is a different user. Personal report Personal report Community · Reddit

Duration: how long the feeling lasts

Some daily users describe control through evening. Morning users report evening or all-day control. One 2.5 mg user still felt reduced appetite during an accidentally missed day. Neither establishes a fixed single-tablet benefit window. Community · Reddit Community · Reddit
Wear-off reports conflict. The unverified capsule author reports hunger after dosing four hours late. A reply questions that interpretation; the author concedes formulation or daily variation might matter. Hunger does not measure clearance. Personal report
After stopping, persistence is uncertain. A capsule-thread respondent describes returning food noise when the bottle ran out, without a precise interval. Earlier reports also discuss rebound; neither supplies a dependable washout-to-hunger timetable. Personal report Community

Cycles, maintenance and breaks

Discussion centers on ongoing use. Community discussion favors tolerable ongoing appetite control over a short bodybuilding cut. Logs track monthly follow-ups and injection-to-pill switches; no standard on/off course emerges. Community Community · Reddit Community · Reddit
Alternate-day experiments are reported, not validated. One 2.5 mg respondent tries alternate days for excessive appetite suppression; others only ask about it. No established break length or lasting weight-control outcome is provided. Community · Reddit

Good to know

Stomach effects can remain disruptive. Reports include nausea, reflux, vomiting, diarrhea or constipation. Some improve; others worsen after an increase or never fully settle. Respondents also describe fatigue, hair-loss concerns or light-headedness severe enough to quit. These experiences do not establish each symptom's cause. Community · Reddit Community · Reddit Community
Serious symptoms and other medicines matter. Warnings include pancreatitis, dehydration-related kidney injury, gallbladder disease, severe stomach problems and anesthesia aspiration. Persistent severe abdominal pain or inability to retain fluids warrants medical attention. Pregnancy, diabetes medicines, contraceptives and interactions need clinician review. Official context
Thyroid warning and overlapping GLP-1 drugs. Personal/family medullary thyroid cancer or MEN2 contraindicates use. Negative rodent findings do not establish human safety. The label discourages another GLP-1 receptor agonist alongside it. Official context
A powder or capsule claim does not verify its contents. Community discussion questions identity and dose accuracy outside branded tablets. Vendor-linked testimonials and claimed testing cannot establish that an unknown product matches Foundayo. Community Personal report

From community discussion

Breakfast versus bedtime has no universal winner. Some prefer breakfast; others report less nausea in the evening. One user cannot separate timing from more regular meals. Early unusual dreams appear in bedtime and first-week accounts without proving a timing effect. Community · Reddit Community · Reddit Community · Reddit
Eating enough can become the harder task. Users discuss smaller portions, protein, fiber, hydration, electrolytes, ginger and resistance training. One workout-focused respondent found dense protein foods uncomfortable and felt stressed by rigid protein targets. Earlier reports also associate greasy meals or alcohol-heavy dinners with reflux; these are experiences, not universal restrictions. Community · Reddit Community · Reddit Community
A convenient switch can still disappoint. A former Zepbound user liked the pill but reported hunger, food noise, brain fog, regain and stomach trouble despite reducing the amount. Other respondents tolerate it or maintain weight; convenience does not predict the result. Community · Reddit Community
Tolerance stories can overreach. A bodybuilding-forum argument claims Orforglipron needs no titration; another poster disputes it. Other community discussion favors slower steps because of GI tolerance. Receptor theories do not establish a safe shortcut or explain every plateau. Community · MESO-Rx Community
Tracking can inform discussion without proving benefit. Community reports include resting-heart-rate tracking and muscle/strength concerns during rapid loss. Protein, training and GI-support combinations complicate attribution. A quieter appetite or improved fitness cannot authenticate a product or guarantee preserved muscle. Community

What trials and prescribing information add

Trials examine sustained weight management. Human trials support weight management during continuing treatment. They do not establish a short cut cycle, a one-off craving blocker or equal results after switching from injections. Official context Official context
Specific capsule/tablet mapping, not a general conversion. Lilly's poster identifies a 17.2 mg tablet as equivalent to the 36 mg investigational capsule. That mapping applies to specified formulations, not unknown powders or other GLP-1 drugs; the headline numbers are not interchangeable personal doses. Official context
Human half-life measurements have different contexts. Current labeling reports 29–49 hours. Pratt's healthy-participant study reports 24.6–35.3 hours after single dosing and 48.1–67.5 hours after repeated daily dosing. These formal measurements come from different study contexts, not a personal appetite clock. Official context Official context